Sanofi ExPEC Vaccine Phase 3 Study Update
Ticker: SNYNF · Form: 6-K · Filed: Feb 13, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, vaccine, pharmaceuticals
TL;DR
Sanofi's ExPEC vaccine Phase 3 trial is on track, enrollment complete.
AI Summary
On February 13, 2025, Sanofi announced an update regarding its Phase 3 clinical study for an extraintestinal pathogenic E. coli (ExPEC) vaccine. The company reported that the study, which began in 2022, has completed enrollment and is progressing as planned. This vaccine aims to prevent infections caused by ExPEC bacteria, which can lead to serious conditions like sepsis and meningitis.
Why It Matters
This update signals continued progress in Sanofi's development of a novel vaccine against a significant bacterial pathogen, potentially impacting public health and the company's future revenue streams.
Risk Assessment
Risk Level: low — The filing is a routine update on a clinical trial's progress and does not contain new financial information or significant strategic changes.
Key Players & Entities
- Sanofi (company) — Registrant
- February 13, 2025 (date) — Press Release Date
- 2022 (date) — Phase 3 Study Start Year
- ExPEC (medical_term) — Vaccine Target
FAQ
What is the purpose of the extraintestinal pathogenic E. coli (ExPEC) vaccine?
The vaccine aims to prevent infections caused by ExPEC bacteria, which can lead to serious conditions such as sepsis and meningitis.
When did Sanofi publish the press release regarding the ExPEC vaccine study?
Sanofi published the press release on February 13, 2025.
What is the current status of the Phase 3 clinical study for the ExPEC vaccine?
The Phase 3 clinical study has completed enrollment and is progressing as planned.
What is Sanofi's SEC file number?
Sanofi's SEC file number is 001-31368.
What form does Sanofi file annually?
Sanofi files annual reports under Form 20-F.
Filing Stats: 181 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-02-13 12:23:44
Filing Documents
- d822073d6k.htm (6-K) — 8KB
- d822073dex991.htm (EX-99.1) — 15KB
- g822073g0213175214657.jpg (GRAPHIC) — 3KB
- 0001193125-25-025839.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SANOFI Dated: February 13, 2025 By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3